{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:52:02Z","timestamp":1791478322220,"version":"4.3.4"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.48172","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T17:03:34Z","timestamp":1644858214000},"page":"e2148172","source":"Crossref","is-referenced-by-count":25,"title":["Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment"],"prefix":"10.1001","volume":"5","author":[{"given":"William S.","family":"Weintraub","sequence":"first","affiliation":[{"name":"MedStar Healthcare Delivery Research Network, MedStar Health Research Institute, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital Heart and Vascular Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zugui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute for Research on Equity and Community Health, ChristianaCare Health System, Newark, Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarahfaye","family":"Dolman","sequence":"additional","affiliation":[{"name":"MedStar Healthcare Delivery Research Network, MedStar Health Research Institute, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Boden","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cardiology Section, Veterans Affairs Boston Healthcare System, Boston, Massachusetts"},{"name":"Department of Medicine, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P.","family":"Bress","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan B.","family":"King","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon K.","family":"Bellows","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel S.","family":"Tajeu","sequence":"additional","affiliation":[{"name":"Health Services Administration and Policy, Temple University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine G.","family":"Derington","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Johnson","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Optum, Eden Prairie, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Andrade","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Optum, Eden Prairie, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"Medical School of Universit\u00e9 de Paris, Paris, France"},{"name":"Cardiology Department, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bichat, Paris, France"},{"name":"French Alliance for Cardiovascular Trials (FACT), INSERM U-1148, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Maryland School of Medicine, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot A.","family":"Brinton","sequence":"additional","affiliation":[{"name":"Utah Lipid Center, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry A.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Office of Health Promotion and Disease Prevention, Department of Medicine, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[{"name":"Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kolm","sequence":"additional","affiliation":[{"name":"Center of Biostatistics, Informatics, and Data Science, MedStar Health Research Institute, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"zoi211325r1","author":"Fruchart","year":"2008","journal-title":"Am J Cardiol"},{"issue":"5","key":"zoi211325r2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1161\/CIRCULATIONAHA.119.044440","article-title":"REDUCE-IT USA: results From the 3146 patients randomized in the United States.","volume":"141","author":"Bhatt","year":"2020","journal-title":"Circulation"},{"issue":"22","key":"zoi211325r3","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"Effects of icosapent ethyl on total ischemic events: from REDUCE-IT.","volume":"73","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"zoi211325r4","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1016\/j.jacc.2019.03.492","article-title":"Risk of total events with icosapent ethyl: can we reduce it?","volume":"73","author":"Granger","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"zoi211325r5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1161\/CIRCULATIONAHA.120.050276","article-title":"Reduction in revascularization with icosapent ethyl: insights from REDUCE-IT revascularization analyses.","volume":"143","author":"Peterson","year":"2021","journal-title":"Circulation."},{"issue":"15","key":"zoi211325r6","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.jacc.2021.08.009","article-title":"Comparative reductions in investigator-reported and adjudicated ischemic events in REDUCE-IT.","volume":"78","author":"Gaba","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"zoi211325r7","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/clc.2017.40.issue-3","article-title":"Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin Cardiol"},{"issue":"1","key":"zoi211325r8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"zoi211325r9","doi-asserted-by":"publisher","first-page":"f1049","DOI":"10.1136\/bmj.f1049","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.","volume":"346","author":"Husereau","year":"2013","journal-title":"BMJ"},{"issue":"10","key":"zoi211325r10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine.","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"zoi211325r11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","article-title":"Competing risk analysis using R: an easy guide for clinicians.","volume":"40","author":"Scrucca","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"zoi211325r13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMsa1616035","article-title":"Cost-effectiveness of intensive versus standard blood-pressure control.","volume":"377","author":"Bress","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi211325r14","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/MLR.0000000000000410","article-title":"Professional fee ratios for US hospital discharge data.","volume":"53","author":"Peterson","year":"2015","journal-title":"Med Care"},{"issue":"1","key":"zoi211325r17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/1475-6773.12612","article-title":"Adjusting health expenditures for inflation: a review of measures for health services research in the United States.","volume":"53","author":"Dunn","year":"2018","journal-title":"Health Serv Res"},{"issue":"7","key":"zoi211325r18","first-page":"1","article-title":"United States life tables, 2017.","volume":"68","author":"Arias","year":"2019","journal-title":"Natl Vital Stat Rep"},{"issue":"14","key":"zoi211325r19","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1161\/CIRCULATIONAHA.114.009985","article-title":"Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial.","volume":"130","author":"Cohen","year":"2014","journal-title":"Circulation"},{"issue":"11","key":"zoi211325r20","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s40273-020-00937-z","article-title":"Estimating transition probabilities from published evidence: a tutorial for decision modelers.","volume":"38","author":"Gidwani","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"14","key":"zoi211325r21","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.113.004042","article-title":"Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study.","volume":"129","author":"Moran","year":"2014","journal-title":"Circulation"},{"issue":"9859","key":"zoi211325r22","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","article-title":"Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.","volume":"380","author":"Murray","year":"2012","journal-title":"Lancet"},{"issue":"7","key":"zoi211325r23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease.","volume":"316","author":"Kazi","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"zoi211325r24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1161\/CIRCOUTCOMES.114.001240","article-title":"Quantifying the utility of taking pills for cardiovascular prevention.","volume":"8","author":"Hutchins","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"5","key":"zoi211325r25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006505","article-title":"Quantifying the utility of taking pills for preventing adverse health outcomes: a cross-sectional survey.","volume":"5","author":"Hutchins","year":"2015","journal-title":"BMJ Open"},{"issue":"1","key":"zoi211325r27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2014.09.078","article-title":"Cost-effectiveness of revascularization strategies: the ASCERT study.","volume":"65","author":"Zhang","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"zoi211325r28","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1161\/CIR.0000000000000042","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines.","volume":"129","author":"Anderson","year":"2014","journal-title":"Circulation"},{"issue":"6","key":"zoi211325r29","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1177\/0962280211419832","article-title":"Probabilistic sensitivity analysis in health economics.","volume":"24","author":"Baio","year":"2015","journal-title":"Stat Methods Med Res"},{"issue":"11","key":"zoi211325r30","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1007\/s12325-015-0264-7","article-title":"A Retrospective study to examine healthcare costs related to cardiovascular events in individuals with hyperlipidemia.","volume":"32","author":"Henk","year":"2015","journal-title":"Adv Ther"},{"issue":"5","key":"zoi211325r31","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jacl.2019.07.004","article-title":"The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy.","volume":"13","author":"Case","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"1","key":"zoi211325r32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.jvca.2016.08.008","article-title":"In-hospital outcomes and complications of coronary artery bypass grafting in the United States between 2008 and 2012.","volume":"31","author":"Moazzami","year":"2017","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"4","key":"zoi211325r33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7326\/M18-1776","article-title":"Cost-effectiveness of alirocumab: a just-in-time analysis based on the ODYSSEY Outcomes Trial.","volume":"170","author":"Kazi","year":"2019","journal-title":"Ann Intern Med"},{"issue":"18","key":"zoi211325r34","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1016\/j.jacc.2020.03.029","article-title":"Cost-effectiveness of alirocumab in patients with acute coronary syndromes: the ODYSSEY OUTCOMES Trial.","volume":"75","author":"Bhatt","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"zoi211325r35","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.jacc.2020.03.037","article-title":"PCSK9 inhibition for therapeutic decision-making: assessing the value.","volume":"75","author":"Weintraub","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"zoi211325r38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1161\/CIRCRESAHA.117.312243","article-title":"Reducing cardiovascular disparities through community-engaged implementation research: a National Heart, Lung, and Blood Institute workshop report.","volume":"122","author":"Mensah","year":"2018","journal-title":"Circ Res"},{"key":"zoi211325r39","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejim.2019.07.001","article-title":"The cost-effectiveness of omega-3 polyunsaturated fatty acids\u2014the Australian healthcare perspective.","volume":"67","author":"Gao","year":"2019","journal-title":"Eur J Intern Med"},{"key":"zoi211325r26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1385\/1-59259-398-4:123","volume-title":"Cardiovascular Health Care Economics","author":"Mahoney","year":"2003"},{"key":"zoi211325r12","unstructured":"Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality. Overview of the National (Nationwide) Inpatient Sample (NIS). Accessed May 14, 2020. https:\/\/www.hcup-us.ahrq.gov\/nisoverview.jsp?"},{"key":"zoi211325r15","unstructured":"Centers for Medicare & Medicaid Services. Health expenditures by age and gender. Accessed July 15, 2020. https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/NationalHealthExpendData\/Age-and-Gender?"},{"key":"zoi211325r16","unstructured":"SSR Health. Home page. Accessed July 15, 2020. https:\/\/www.ssrhealth.com\/"},{"key":"zoi211325r36","unstructured":"IBM. IBM Micromedex RED BOOK. Accessed July 15, 2020. https:\/\/www.ibm.com\/products\/micromedex-red-book"},{"key":"zoi211325r37","unstructured":"Institute for Clinical and Economic Review. Cardiovascular disease: additive therapies. Accessed July 15, 2020. https:\/\/icer.org\/assessment\/cvd-additive-therapies-2019\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2789004\/weintraub_2022_oi_211325_1644261194.85902.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T17:03:39Z","timestamp":1644858219000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2789004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.48172","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]}}}